FDA Extends Review Period for Novo Nordisk's Denecimig Hemophilia Treatment
The U.S. Food and Drug Administration (FDA) has extended its review period for Novo Nordisk’s Biologics License Application (BLA) seeking approval of denecimig, a treatment for hemophilia A. The extension is attributed to ongoing facility remediation activities at the manufacturing site responsible for producing the drug. Novo Nordisk stated that these remediation efforts are necessary but have delayed regulatory review timelines. Hemophilia A is a rare bleeding disorder caused by insufficient clotting factor VIII in the blood, and denecimig represents a potential new therapy option if approved. The delay could affect investor sentiment around Novo Nordisk’s pipeline progress for hematology treatments.
Tickers: $NVO
Topics: drug approval hemophilia A pharmaceuticals